期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

拓扑替康联合环磷酰胺治疗儿童神经母细胞瘤 被引量：3

Topotecan with cyclophosphamide in treatment of children with neuroblastoma
下载PDF
导出
摘要 目的：观察评价拓扑替康联合环磷酰胺治疗神经母细胞瘤的疗效和毒性。方法：14例神经母细胞瘤患儿，应用拓扑替康联舍环磷酰胺联合静脉用药。大剂量应用环磷酰胺[70mg／（kg·d）×2d]和拓扑替康[2mg／（m^2·d）×3d]。其中12例治疗2～13个周期，进行疗效和不良反应评价。结果：12例患者中，进展3例，稳定及缓解9例，总有效率为75％。不良反应主要为骨髓抑制和消化道反应，但对症治疗后，无相关性死亡。结论：拓扑替康联合环磷酰胺治疗儿童神经母细胞瘤安全有效。 OBJECTIVE： To evaluate the effect and toxicity of topotecan with cyclophosphamide in the treatment of children with neuroblastoma. METHODS： Fourtheen patients with neuroblstoma underwent the intravenous chemotherapy of topotecan and cyclophosphamide. High dose of cyclophosphamide [70 mg/（kg·d）×2 d] and topotecan [2 mg/（m^2·d）×3 d） were used in 12 patients for 2-13 courses, and the outcomes and side effects of this therapeutics were evaluated. RESULTS： Three patients got progressive and the other 9 got remission or stable. The total efficiency was 75% in this group. The side effects of this combined chemotherapy were myelosuppression and digestive side effect. No side effect related to death was found in this group after heterotherapy. CONCLUSION： The combination of chemotherapy with topotecan and cyclophosphamide is safe ard effective in the treatment of neuroblastoma in children.
作者 蔡炜嵩 张可仞 张锦华 王维林
机构地区 中国医科大学第二临床学院盛京医院小儿外科 中国医科大学第二临床学院盛京医院血液室
出处 《中华肿瘤防治杂志》 CAS 2006年第11期855-856,共2页 Chinese Journal of Cancer Prevention and Treatment
基金 国家自然科学基金资助项目(39470739) 香港S.K.Yee医学基金资助项目
关键词 神经母细胞瘤/药物疗法 拓泊替坎/投药和剂量 环磷酰胺/投药和剂量 儿童 neuroblastoma/drug therapy topotecan/administration ＆ dosage cyclophosphamide/administration ＆ dosage child
分类号 R739.4 [医药卫生—肿瘤]
  • 相关文献

参考文献8

二级参考文献18

  • 1[美]萨姆布鲁克J拉塞尔Dw. 黄培堂等译.分子克隆:第三版[M].北京:科学出版社,2002.597-701，1271-1313.
  • 2[1]Schiller JH. Topotecan in small cell lung cancer[J].Semin Oncol,1997,24(6 Suppl 20):27-33.
  • 3[2]Mitsui I,Kumazawa E,Hirota Y,et al. A new water-soluble camptothecin derivative,DX-8951f,exhibit potent antitumor activity against human tumors in VITRO and in VIVO[J].Jpn J Cancer Res,1995,86(8):776-782.
  • 4[3]Jonsson E,Fridborg H,Csoka K,et al. Cytotoxic activity of topotecan in human tumor cells from patients[J].Br J Cancer,1997,76(2):211-219.
  • 5[4]Roth BJ,Johnson DH,Einhom LH,et al. Randomized study of cyclophosphamide,doxorubicin,and vincristine versus etoposide and cisplatin versus altemation of these two regimens in extensive small-cell lung cancer:a phase Ⅲ trial of southeastern Cancer Study Group[J].J Clin Oncol,1992,10(2):282-291.
  • 6[5]Shepherd FA,Evans WK,Mac Comick R,et al. Cyclophosphamide,doxorubicin,and vincristine in etoposide and cisplatin-resistant small cell lung cancer[J].Cancer Treat Rep,1987,71(10):941-944.
  • 7[6]Schiller JH,Kim K,Hutson P,et al. Rhase Ⅱ study of topotecan in patients with extensive-stage small-cell carcinoma of the lung:an Eastern cooperative Oncology Group Trail[J].J Clin Oncol,1996,14(8):2345-2352.
  • 8[7]Von Pawel J,Schiller JH,Shepherd FA,et al. Topotecan versus cyclophosphamide,doxorubicin,and vincristine for the treatment of recurrent small-cell lung cancer[J].J Clin Oncol,1999,17(2):658-667.
  • 9[8]Rowinsky EK,Grochow LB,Bendricks CB,et al. Phase I and pharmacologic study of topotecan:a novel topoisomerase I inhibitor[J].J Clin Oncol,1992,10(4):647-656.
  • 10[9]Kollmannsberger C,Mross K,Jakob A,et al. Topotecan-A novel topoisomerase I inhibitor:pharmacology and clinical experience[J].Oncology,1999,56(1):1-12.

共引文献5

同被引文献27

  • 1Maris J M, Hogarty M D, Bagatell R, et al. Neuroblastoma [J]. Lancet, 2007, 369(9579):2106-2120.
  • 2lshola T A, Chung D H. Neuroblastoma[J]. Surg Oncol, 2007, 16(3) : 149-156.
  • 3Zhang L, Smith K M, Chong A L, et al. In vivo antitumor and antimetastatic activity of sunitinib in preclinical neuroblastoma mousemodel[J]. Neoplasia, 2009,11(5): 426-435.
  • 4Sims T L Jr, Hamner J B, Bush R A, et al. Neural progenitor cell-mediated delivery of osteoprotegerin limits disease progression in a preclinical model of neuroblastoma bone metastasis[J]. J Pediatr Surg, 2009, 44(1): 204-210; discussion 210-211.
  • 5Peng H, Sohara Y, Moats R A, et al. The activity of zoledronic Acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and tumor cell survival and proliferation[J]. Cancer Res, 2007,67(19) :9346-9355.
  • 6Meier R, Muhlethaler-Mottet A, Flahaut M, et al. The chemokine receptor CXCR4 strongly promotes neuroblastoma primary tumour and metastatic growth, but not invasion[J]. PLos One, 2007, 2(10): 1016.
  • 7van Golen C M, Schwab T S, Kim B, et al. Insulin-like growth factor-1 receptor expression regulates neuroblastoma metastasis to bone[J]. Cancer Res, 2006, 66(13) : 6570-6578.
  • 8Roodman G D. Mechanisms of bone metastasis[J]. N Engi J Med, 2004, 351(2): 195-196.
  • 9Matthay KK, Villablanca JG, Seeger RC, etal. Treatment of highrisk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid [ J ]. N Engl J Med, 1999,341(16) :1165-1173.
  • 10Van Cutsem E, Kohne CH, Lang I, et al. Cetuximab plus irinotecan, fluorouracil, and leueovorin as first-line treatment tkw metastatic eoloreetal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status[ J]. J Clin Oneol, 2011,29 (15) :2011-2019.

引证文献3

二级引证文献6

中华肿瘤防治杂志
2006年 第11期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部